Erlotinib - Erlocip

ERLOCIP Tablets are indicated for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations. ERLOCIP Tablets are also indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based, first-line chemotherapy. ERLOCIP Tablets is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. When prescribing ERLOCIP Tablets, factors associated with prolonged survival should be taken into account.

ERLOCIP ........... Container pack of 30 Tablets